EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment decisions based on HBV DNA

Young-Suk Lim iD

Journal of Viral Hepatitis · 2024

DOI: 10.1111/jvh.13956 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von Young-Suk Lim. Beteiligte Einrichtung: Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinoma, Hepatocellular, DNA, Viral, Hepatitis B virus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The most common cause of hepatocellular carcinoma (HCC) worldwide is chronic hepatitis B virus (HBV) infection (CHB). Long‐term suppression of HBV replication by antiviral treatment reduces the risk of HCC and mortality. Nonetheless, only 2.2% of CHB patients globally received the treatment in 2019. Current international CHB guidelines recommend antiviral treatment only in subsets of patients with clear evidence of liver damage as evidenced by elevation of alanine aminotransferase (ALT). This review aims to provide existing evidence that the risk of HCC is significantly associated with serum levels of HBV DNA, and the association is non‐linear parabolic, in both untreated and treated CHB patients, regardless of HBeAg status or ALT levels. Therefore, the decision for the antiviral treatment should be based on serum HBV DNA levels and age, rather than ALT levels or liver biopsy, to reduce or prevent the risk of HCC in CHB patients. The potential impact and cost‐effectiveness data on early antiviral treatment initiation were also collated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCarcinoma, HepatocellularDNA, ViralHepatitis B virusHepatitis B, ChronicLiver NeoplasmsHumansAlanine TransaminaseClinical Decision-Making

Stichwörter der Autor:innen

grey zonehepatitis B virushepatocellular carcinomaindeterminate phaseliver cancer

Substanzen

Alanine TransaminaseAntiviral AgentsDNA, Viral

Autor:innen und Institutionen

  • Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Young-Suk Lim

Zitieren

APA

Lim, Y. S. (2024). Treatment decisions based on HBV DNA. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13956

Vancouver

Lim YS. Treatment decisions based on HBV DNA. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.13956

BibTeX
@article{Lim2024,
  author = {Lim, Young-Suk},
  title = {Treatment decisions based on HBV DNA},
  journal = {Journal of Viral Hepatitis},
  year = {2024},
  doi = {10.1111/jvh.13956}
}
Kostenlos starten →